Vifor Pharma comments on media speculation

Rhea-AI Summary

Vifor Pharma Group is currently in discussions with CSL for a potential transaction, though no decisions or timelines have been established. The company has chosen not to comment further on the discussions at this time. Vifor Pharma aims to lead in iron deficiency and nephrology therapies, focusing on innovative patient solutions. The company is headquartered in Switzerland and is publicly listed on the SIX Swiss Exchange under the ticker VIFN.

Positive

• Ongoing discussions with CSL could lead to strategic opportunities.

Negative

• Lack of concrete details regarding the transaction raises uncertainty.

ST. GALLEN, Switzerland--(BUSINESS WIRE)--

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions.

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211212005150/en/

Media Relations

Nathalie Ponnier

Global Head Corporate Communications

+41 79 957 96 73

media@viforpharma.com

Investor Relations

Julien Vignot

Head of Investor Relations

+41 58 851 66 90

investors@viforpharma.com

Source: Vifor Pharma Group

FAQ

What is the current status of Vifor Pharma's discussions with CSL?

Vifor Pharma is in discussions with CSL about a potential transaction, but no decisions have been made yet.

What is Vifor Pharma Group's focus in the pharmaceutical industry?

Vifor Pharma Group aims to become a leader in iron deficiency, nephrology, and cardio-renal therapies.

Where is Vifor Pharma Group headquartered?

Vifor Pharma Group is headquartered in Switzerland.

On which stock exchange is Vifor Pharma Group listed?

Vifor Pharma Group is listed on the SIX Swiss Exchange under the ticker VIFN.